본문 바로가기
KERD
논문KCI 등재

노년기 우울증에서의 항우울제 치료에 대한 고찰

Review of Antidepressants Treatment in Late-Life Depression

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

초록

Late-life depression (LLD) refers to depressive syndromes defined in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and in the International Classification of Diseases-10 (ICD-10) that arise in adults older than age 65 years. LLD often affects people with chronic medical diseases, cognitive impairment, or other forms of disability. The phenomenology of LLD differs in part from that of early-life depression. Antidepressants appear to have a neutral or protective effect against suicidal ideation or behavior in the elderly despite having the risk of opposite effect in children, adolescents, and young adults. The treatment of depression may be divided into acute, continuation, and maintenance phases. Currently available antidepressant medications represent several classes of agents with similar antidepressant efficacy. Differences in side effect profile, interactions, and out-of-pocket cost are important determinants in the choice of medication for an elderly patient. To minimize side effects, starting doses for older adults may be lower than those for younger adults, but older adults often require full adults doses for an adequate response. Antidepressants are as effective when given to elderly individuals as they are when given to younger adults. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) the antidepressants of choice, followed by bupropion, and mirtazapine. Tricyclic antidepressants (TCAs) are effective but are no longer considered to be first-line treatments because of their side effects.

Abstract

Late-life depression (LLD) refers to depressive syndromes defined in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and in the International Classification of Diseases-10 (ICD-10) that arise in adults older than age 65 years. LLD often affects people with chronic medical diseases, cognitive impairment, or other forms of disability. The phenomenology of LLD differs in part from that of early-life depression. Antidepressants appear to have a neutral or protective effect against suicidal ideation or behavior in the elderly despite having the risk of opposite effect in children, adolescents, and young adults. The treatment of depression may be divided into acute, continuation, and maintenance phases. Currently available antidepressant medications represent several classes of agents with similar antidepressant efficacy. Differences in side effect profile, interactions, and out-of-pocket cost are important determinants in the choice of medication for an elderly patient. To minimize side effects, starting doses for older adults may be lower than those for younger adults, but older adults often require full adults doses for an adequate response. Antidepressants are as effective when given to elderly individuals as they are when given to younger adults. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) the antidepressants of choice, followed by bupropion, and mirtazapine. Tricyclic antidepressants (TCAs) are effective but are no longer considered to be first-line treatments because of their side effects.

참고문헌 (57)

  1. Alexopoulos GS, "Depression in the elderly", Lancet, 365, pp.1961~1970 (2005)
  2. Alexopoulos GS, "Comorbidity of late life depression: an opportunity for research on mechanisms and treatment", Biol Psychiatry, 52, pp.543~558 (2002)
  3. Frasure-Smith N, "Depression following myocardial infarction. Impact on 6-month survival", JAMA, 270, pp.1819~1825 (1993)
  4. Hegeman JM, "Phenomenology of depression in older compared with younger adults: meta-analysis", Br J Psychiatry, 200, pp.275~281 (2012)
  5. Cheon JS, "Psychosocial factors associated with suicidal idea among Korean elderly", J Korean Geriatr Psychiatry, 9, pp.132~139 (2005)
  6. Miniño AM, "Deaths: final data for 2000", Natl Vital Stat Rep, 50, pp.1~119 (2002)
  7. Conwell Y, "Age differences in behaviors leading to completed suicide", Am J Geriatr Psychiatry, 6, pp.122~126 (1998)
  8. Murphy SL, "Deaths: final data for 1998", Natl Vital Stat Rep, 48, pp.1~105 (2000)
  9. Public Health Service. National strategy for suicide prevention: goals and objectives for action, "United States", Public Health Service, ~ (2001)
  10. Kuehn BM, "FDA panel seeks to balance risks in warnings for antidepressants", JAMA, 297, pp.573~574 (2007)
  11. Unützer J, "Older adults with severe, treatment-resistant depression", JAMA, 308, pp.909~918 (2012)
  12. Pinquart M, "Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy", Am J Psychiatry, 163, pp.1493~1501 (2006)
  13. Keller MB, "A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression", N Engl J Med, 342, pp.1462~1470 (2000)
  14. Ellison JM, "Depression in later life: an overview with treatment recommendations", Psychiatr Clin North Am, 35, pp.203~229 (2012)
  15. Salzman C, "Drug and ECT treatment of depression in the elderly, 1996-2001: a literature review", Biol Psychiatry, 52, pp.265~284 (2002)
  16. Alexopoulos GS, "Expert Consensus Panel for Pharmacotherapy of Depressive Disorders in Older Patients. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients", Postgrad Med, pp.1~86 (2001)
  17. Rojas-Fernandez CH, "Considerations in the treatment of geriatric depression: Overview of pharmacotherapeutic and psychotherapeutic treatment interventions", Res Gerontol Nurs, 3, pp.176~186 (2010)
  18. Sackeim HA, "Optimal length of antidepressant trials in late-life depression", J Clin Psychopharmacol, 25(4 Suppl 1), pp.S34~S37 (2005)
  19. Mulsant BH, "What is the optimal duration of a short-term antidepressant trial when treating geriatric depression?", J Clin Psychopharmacol, 26, pp.113~120 (2006)
  20. Zis AP, "Prediction of relapse in recurrent affective disorder", Psychopharmacol Bull, 16, pp.47~49 (1980)
  21. Charney DS, "Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life", Arch Gen Psychiatry, 60, pp.664~672 (2003)
  22. Unützer J, "Clinical practice. Late-life depression", N Engl J Med, 357, pp.2269~2276 (2007)
  23. Flint AJ, "The effect of treatment on the two-year course of late-life depression", Br J Psychiatry, 170, pp.268~272 (1997)
  24. Ellison JM, "Pharmacotherapy of late-life depression: evidence-based recommendations, In Mood disorders in later life", pp.239~290 (2009), Informa Healthcare
  25. Wilson K, "A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis", Int J Geriatr Psychiatry, 19, pp.754~762 (2004)
  26. Fick DM, "Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts", Arch Intern Med, 163, pp.2716~2724 (2003)
  27. Stahl SM, "Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants", CNS Spectr, 13, pp.855~870 (2008)
  28. Robinson DS, "The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability", J Affect Disord, 105, pp.15~23 (2008)
  29. Alexopoulos GS, "Pharmacotherapy for late-life depression", J Clin Psychiatry, 72, pp.e04~ (2011)
  30. Thébault JJ, "Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor", Pharmacotherapy, 24, pp.1295~1305 (2004)
  31. Canton J, "Optimal treatment of social phobia: systematic review and meta-analysis", Neuropsychiatr Dis Treat, 8, pp.203~215 (2012)
  32. Draper B, "Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly", Drugs Aging, 25, pp.501~519 (2008)
  33. Alexopoulos GS, "The inflammation hypothesis in geriatric depression", Int J Geriatr Psychiatry, 26, pp.1109~1118 (2011)
  34. Goldstein DJ, "Fluoxetine in medically stable, depressed geriatric patients: effects on weight", J Clin Psychopharmacol, 17, pp.365~369 (1997)
  35. Jacob S, "Hyponatremia associated with selective serotonin- reuptake inhibitors in older adults", Ann Pharmacother, 40, pp.1618~1622 (2006)
  36. Lane RM, "SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment", J Psychopharmacol, 12, pp.192~214 (1998)
  37. Boyer EW, "The serotonin syndrome", N Engl J Med, 352, pp.1112~1120 (2005)
  38. Kent JM, "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression", Lancet, 355, pp.911~918 (2000)
  39. Thase ME, "Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients", J Clin Psychiatry, 59, pp.502~508 (1998)
  40. Wellington K, "Venlafaxine extended-release: a review of its use in the management of major depression", CNS Drugs, 15, pp.643~669 (2001)
  41. Raskin J, "Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial", Am J Psychiatry, 164, pp.900~909 (2007)
  42. Nelson JC, "Duloxetine for the treatment of major depressive disorder in older patients", Am J Geriatr Psychiatry, 13, pp.227~235 (2005)
  43. Fishbain D, "Evidence-based data on pain relief with antidepressants", Ann Med, 32, pp.305~316 (2000)
  44. Spina E, "Clinically significant drug interactions with antidepressants in the elderly", Drugs Aging, 19, pp.299~320 (2002)
  45. Nierenberg AA, "Trazodone for antidepressant-associated insomnia", Am J Psychiatry, 151, pp.1069~1072 (1994)
  46. Roose SP, "Late-life depression" (2004), Oxford Univeristy Press;
  47. Owen JR, "New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine", Depress Anxiety, 7(Suppl 1), pp.24~32 (1998)
  48. Eyding D, "Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials", BMJ, 41, pp.c4737~ (2010)
  49. Katona C, "Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial", J Affect Disord, 55, pp.203~213 (1999)
  50. McEwen BS, "Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine", Mol Psychiatry, 10, pp.525~537 (2005)
  51. Kasper S, "Neurobiological and clinical effects of the antidepressant tianeptine", CNS Drugs, 22, pp.15~26 (2008)
  52. Wagstaff AJ, "Tianeptine: a review of its use in depressive disorders", CNS Drugs, 15, pp.231~259 (2001)
  53. Demotes-Mainard F, "Pharmacokinetics of the antidepressant tianeptine at steady state in the elderly", J Clin Pharmacol, 31, pp.174~178 (1991)
  54. Mottram P, "Antidepressants for depressed elderly", Cochrane Database Syst Rev, pp.CD003491~ (2006)
  55. Wilkinson P, "Continuation and maintenance treatments for depression in older people", Cochrane Database Syst Rev, 11, pp.CD006727~ (2012)
  56. Mittmann N, "The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis", J Affect Disord, 46, pp.191~217 (1997)
  57. DeVane CL, "Differential pharmacology of newer antidepressants", J Clin Psychiatry, 59(Suppl 20), pp.85~93 (1998)

관련 논문AI추천

이 간행물의 다른 논문 (6건)